Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups

Details for Australian Patent Application No. 2004279855 (hide)

Owner Vertex Pharmaceuticals Incorporated

Inventors Hamilton, Matthew; Singh, Ashvani K.; Hadida Ruah, Sara S.; Miller, Mark T.; Grootenhuis, Peter D.J.

Agent Cullen & Co

Pub. Number AU-A-2004279855

PCT Pub. Number WO2005/035514

Priority 60/509,642 08.10.03 US

Filing date 8 October 2004

Wipo publication date 21 April 2005

International Classifications

A61K 31/00 (2006.01)

A61K 31/335 (2006.01) - having oxygen as the only ring hetero atom, e.g. fungichromin

A61K 31/38 (2006.01) - having sulfur as a ring hetero atom

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

A61K 31/41 (2006.01) - having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

A61K 31/435 (2006.01) - having six-membered rings with one nitrogen as the only ring hetero atom

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

C07C 233/11 (2006.01) Carboxylic acid amides

C07C 233/22 (2006.01) Carboxylic acid amides

C07C 233/60 (2006.01) Carboxylic acid amides

C07C 233/65 (2006.01) Carboxylic acid amides

C07C 233/73 (2006.01) Carboxylic acid amides

C07C 235/34 (2006.01) Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms

C07C 235/46 (2006.01) Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms

C07C 235/48 (2006.01) Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms

C07C 307/00 (2006.01) Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups

C07C 311/16 (2006.01) Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups

C07C 311/17 (2006.01) Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups

C07D 209/42 (2006.01) Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 213/82 (2006.01) Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

C07D 215/54 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

C07D 215/56 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

Event Publications

18 May 2006 PCT application entered the National Phase

  PCT publication WO2005/035514 Priority application(s): WO2005/035514

12 May 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004279868-Dispenser apparatus

2004279837-A method for the treatment of malignant diseases by inhibiting nucleolin